What is Semnur Pharmaceuticals Inc.'s earnings per share (EPS)?

Semnur Pharmaceuticals Inc. (SMNR) reported diluted earnings per share of $-0.78 for fiscal year 2025. This represents a -3800.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Semnur Pharmaceuticals Inc. Financials

SMNR

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Semnur Pharmaceuticals Inc. (SMNR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Semnur Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Semnur Pharmaceuticals Inc.'s current ratio of 0.06 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.78

YoY-3800.0%

Semnur Pharmaceuticals Inc. earned $-0.78 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 3800.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$20K

YoY+66.7%

Semnur Pharmaceuticals Inc. held $20K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

230M

YoY+15.1%

Semnur Pharmaceuticals Inc. had 230M shares outstanding in fiscal year 2025. This represents an increase of 15.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.5M

YoY+49.0%

Semnur Pharmaceuticals Inc. invested $2.5M in research and development in fiscal year 2025. This represents an increase of 49.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SMNR Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$2.5M+49.0%	$1.7M	N/A	N/A
SG&A Expenses	N/A	$3.0M	N/A	N/A
Operating Income	N/A	-$4.7M-47.8%	-$3.2M	N/A
Interest Expense	N/A	$96K+160.8%	$37K	N/A
Income Tax	$0	$0	N/A	N/A
Net Income	N/A	-$4.7M-841.5%	$633K+250.8%	-$419K
EPS (Diluted)	$-0.78-3800.0%	$-0.02	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.1M	N/A	N/A	N/A	$233K	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	$1.1M	N/A	N/A
Operating Income	N/A	N/A	-$375K-52.0%	-$247K	N/A	-$1.3M-671.8%	-$168K+54.3%	-$368K
Interest Expense	N/A	N/A	$28K+5.1%	$27K	N/A	$25K+9.2%	$23K+8.2%	$21K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$999K-50.2%	-$665K-297.5%	-$167K+87.1%	-$1.3M-16.9%	-$1.1M+26.3%	-$1.5M
EPS (Diluted)	N/A	$-0.76	N/A	N/A	N/A	$-0.01	N/A	N/A

SMNR Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$1.3M-79.9%	$6.7M-86.8%	$50.7M-41.3%	$86.3M
Current Assets	$596K-90.1%	$6.0M+2762.4%	$209K-76.9%	$908K
Cash & Equivalents	$20K+66.7%	$12K-94.1%	$204K-75.1%	$820K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$22.1M-55.3%	$49.5M-44.3%	$88.8M-0.9%	$89.6M
Current Liabilities	$10.2M+28951.4%	$35K-99.4%	$5.6M+333.9%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$20.8M+51.5%	-$42.8M-12.3%	-$38.1M-1064.5%	-$3.3M
Retained Earnings	-$275.8M-139.0%	-$115.4M-1293.1%	-$8.3M-153.2%	-$3.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.3M+73.9%	$774K+37.6%	$562K-93.9%	$9.1M+36.9%	$6.7M-25.1%	$8.9M-82.9%	$52.1M+1.5%	$51.3M
Current Assets	$596K+601.2%	$85K+501.0%	$14K+417.0%	$3K-100.0%	$6.0M+16821.6%	$35K-19.1%	$44K-33.1%	$65K
Cash & Equivalents	$20K-76.5%	$85K+67360.3%	$126-95.4%	$3K-77.2%	$12K-7.7%	$13K+766.7%	$2K+48.1%	$1K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$22.1M+43.8%	$15.4M-65.9%	$45.0M-14.4%	$52.6M+6.3%	$49.5M-2.9%	$50.9M-45.1%	$92.8M+2.1%	$90.9M
Current Liabilities	$10.2M+1.4%	$10.0M+21.3%	$8.3M+5.3%	$7.9M+22333.5%	$35K-99.5%	$6.6M+4.4%	$6.3M+5.3%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$20.8M-42.2%	-$14.6M+67.2%	-$44.4M-2.3%	-$43.4M-1.6%	-$42.8M-1.8%	-$42.0M-3.2%	-$40.7M-2.8%	-$39.6M
Retained Earnings	-$275.8M-2.3%	-$269.6M-2319.9%	-$11.1M-3.8%	-$10.7M+90.7%	-$115.4M-1121.5%	-$9.4M-3.1%	-$9.2M-3.9%	-$8.8M

SMNR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$5.9M-20.0%	-$4.9M-672.9%	-$633K-48.5%	-$426K
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$39.7M+147.2%	-$84.2M
Financing Cash Flow	$5.9M+20.1%	$4.9M+112.3%	-$39.7M-146.5%	$85.4M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$40.5M	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$3.6M-73.4%	-$2.1M-2895.8%	-$69K+39.2%	-$114K+91.9%	-$1.4M+53.0%	-$3.0M-2515.7%	-$115K+69.4%	-$374K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Financing Cash Flow	$3.5M	N/A	N/A	$100K-92.9%	$1.4M-56.1%	$3.2M+2682.0%	$115K-32.6%	$171K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A

SMNR Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	N/A	-70.2%-71.4pp	1.3%+1.7pp	-0.5%
Current Ratio	0.06-171.2	171.29+171.2	0.04-0.7	0.70
Debt-to-Equity	-1.06+0.1	-1.16+1.2	-2.33+25.0	-27.37
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	-177.6%-170.3pp	-7.3%-4.8pp	-2.5%+12.0pp	-14.5%-12.4pp	-2.1%+0.8pp	-2.9%
Current Ratio	0.06+0.1	0.010.0	0.000.0	0.00-171.3	171.29+171.3	0.010.0	0.010.0	0.01
Debt-to-Equity	-1.06-0.0	-1.05-0.0	-1.01+0.2	-1.21-0.1	-1.16+0.1	-1.21+1.1	-2.28+0.0	-2.30
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$20.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Semnur Pharmaceuticals Inc.'s operating cash flow?

Semnur Pharmaceuticals Inc. (SMNR) generated -$5.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Semnur Pharmaceuticals Inc.'s total assets?

Semnur Pharmaceuticals Inc. (SMNR) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Semnur Pharmaceuticals Inc. spend on research and development?

Semnur Pharmaceuticals Inc. (SMNR) invested $2.5M in research and development during fiscal year 2025.

How many shares does Semnur Pharmaceuticals Inc. have outstanding?

Semnur Pharmaceuticals Inc. (SMNR) had 230M shares outstanding as of fiscal year 2025.

What is Semnur Pharmaceuticals Inc.'s current ratio?

Semnur Pharmaceuticals Inc. (SMNR) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Semnur Pharmaceuticals Inc.'s debt-to-equity ratio?

Semnur Pharmaceuticals Inc. (SMNR) had a debt-to-equity ratio of -1.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Semnur Pharmaceuticals Inc.'s cash runway?

Based on fiscal year 2025 data, Semnur Pharmaceuticals Inc. (SMNR) had $20K in cash against an annual operating cash burn of $5.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Semnur Pharmaceuticals Inc.'s debt-to-equity ratio negative or unusual?

Semnur Pharmaceuticals Inc. (SMNR) has negative shareholder equity of -$20.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Semnur Pharmaceuticals Inc.?

Semnur Pharmaceuticals Inc. (SMNR) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.